W. Fares

发表

Risk factors for presence and severity of pulmonary embolism in patients with deep venous thrombosis.

T. Sarac, N. Huynh, A. Dardik, 2018, Journal of vascular surgery. Venous and lymphatic disorders.

Complexity of macrophage migration inhibitory factor (MIF) and other angiogenic biomarkers profiling in pulmonary arterial hypertension

R. Bucala, Patty J. Lee, M. Sauler, 2017, Pulmonary circulation.

Netrin‐1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin‐Induced Pulmonary Fibrosis

L. Niklason, Yuwei Cheng, A. Eichmann, 2016, Arthritis & rheumatology.

Hypercoagulability in Pulmonary Hypertension.

W. Fares, I. Bazan, Wassim H. Fares, 2018, Clinics in chest medicine.

Management of Right Heart Failure in the Intensive Care Unit.

W. Fares, C. Kholdani, Wassim H. Fares, 2015, Clinics in chest medicine.

of Right Heart Failure in the Intensive Care Unit

W. Fares, C. Kholdani, Wassim H. Fares, 2015 .

Review of the Ongoing Story of Appetite Suppressants, Serotonin Pathway, and Pulmonary Vascular Disease.

W. Fares, I. Bazan, Wassim H. Fares, 2016, The American journal of cardiology.

Pulmonary Hypertension Prevalence and Prognosis in a Cohort of Patients with Hereditary Hemorrhagic Telangiectasia Undergoing Embolization of Pulmonary Arteriovenous Malformations

L. Young, G. Garcia‐Tsao, J. Pollak, 2017, American journal of respiratory and critical care medicine.

Hypercoagulabil ity in Pulmonary Hypertension

W. Fares, I. Bazan, Wassim H. Fares, 2018 .

Pulmonary hypertension in patients with interstitial lung disease.

D. Bouros, T. Karampitsakos, W. Fares, 2018, Pulmonary pharmacology & therapeutics.

Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension

Jamey D. Young, Robert A. Egnatchik, Thong Luong, 2017, Pulmonary circulation.

Thermodilution and Fick cardiac outputs differ: impact on pulmonary hypertension evaluation.

W. Rosamond, P. Chang, G. Stouffer, 2012, Canadian respiratory journal.

Pulmonary Hypertension in Obstructive Sleep Apnea: Is It Clinically Significant? a Critical Analysis of the Association and Pathophysiology Author(s)

V. Mohsenin, W. Fares, C. Kholdani, 2022 .

Do single or sequential measurements of leptin and adiponectin in plasma have prognostic value in pulmonary arterial hypertension?

R. Dweik, Wael Dakkak, A. Tonelli, 2016, Pulmonary circulation.

A 49-Year-Old Man with Subacute Respiratory Failure and Interstitial Lung Opacities

José Costa, V. Brady, W. Fares, 2017, The American journal of case reports.

The other vascular beds in pulmonary arterial hypertension. Surrogates or associated?

W. Fares, Wassim H. Fares, 2014, Annals of the American Thoracic Society.

Safety and feasibility of obtaining wedged pulmonary artery samples and differential distribution of biomarkers in pulmonary hypertension

A. Ghio, R. Aris, W. Fares, 2012, Pulmonary circulation.

Reduced RVSWI Is Associated With Increased Mortality in Connective Tissue Disease Associated Pulmonary Arterial Hypertension

Y. Rao, K. Highland, W. Fares, 2020, Frontiers in Cardiovascular Medicine.

S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension

Ferhaan Ahmad, N. Kaminski, K. Gibson, 2018, Respirology.

A systematic review of transition studies of pulmonary arterial hypertension specific medications

J. Wirth, R. Tedford, W. Fares, 2017, Pulmonary circulation.

The ‘availability’ bias: underappreciated but with major potential implications

W. Fares, Wassim H. Fares, 2014, Critical Care.

Characteristics of provoked deep venous thrombosis in a tertiary care center.

N. Huynh, A. Dardik, W. Fares, 2017, Journal of vascular surgery. Venous and lymphatic disorders.

Lupus-Associated Pulmonary Arterial Hypertension: Variable Course and Importance of Prompt Recognition

C. Brunet, W. Fares, T. Trow, 2015, Case reports in medicine.

An unusual case of chest pain and dyspnea on exertion

P. Bonde, C. Britto, I. Oliva, 2013 .

Chronic Thromboembolic Pulmonary Hypertension: A Worldwide View of How Far We Have Come

W. Fares, G. Heresi, Wassim H. Fares, 2016, Lung.

Mitochondrial dysfunction and pulmonary hypertension: cause, effect, or both.

Patty J. Lee, W. Fares, Yi Zhang, 2018, American journal of physiology. Lung cellular and molecular physiology.

Not all catheter-days are equal.

W. Fares, 2013, Critical care medicine.

Persistent Left Superior Vena Cava Identified During Central Line Placement: A Case Report.

J. Yankaskas, W. Fares, K. Birchard, 2011, Respiratory medicine CME.

PECAM-1 is Associated WithOutcomes and Response to Treatment in Pulmonary Arterial Hypertension.

T. Ahmad, Patty J. Lee, M. Sauler, 2020, The American journal of cardiology.

Is postoperative atrial fibrillation in patients undergoing noncardiothoracic surgery an important problem

Ashish Aneja, W. Fares, 2006 .

Standard nonspecific therapies in the management of pulmonary arterial hypertension.

M. Sauler, W. Fares, T. Trow, 2013, Clinics in chest medicine.

Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: A review.

E. Herzog, W. Fares, L. Buckley, 2018, Respiratory medicine.

Novel Mechanisms of Disease: Network Biology and MicroRNA Signaling in Pulmonary Hypertension

K. Pandit, N. Kaminski, W. Fares, 2016 .